Investigational Drug Information for Poziotinib
✉ Email this page to a colleague
What is the drug development status for Poziotinib?
Poziotinib is an investigational drug.
There have been 21 clinical trials for Poziotinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 12th 2022.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Breast Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are Spectrum Pharmaceuticals, Inc, Hanmi Pharmaceutical Company Limited, and National OncoVenture.
There are thirty-one US patents protecting this investigational drug and four hundred and twenty-eight international patents.
Summary for Poziotinib
| US Patents | 31 |
| International Patents | 428 |
| US Patent Applications | 197 |
| WIPO Patent Applications | 195 |
| Japanese Patent Applications | 29 |
| Clinical Trial Progress | Phase 2 (2022-05-12) |
| Vendors | 59 |
Recent Clinical Trials for Poziotinib
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations | Spectrum Pharmaceuticals, Inc | Phase 3 |
| Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer | M.D. Anderson Cancer Center | Phase 2 |
| A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants | Spectrum Pharmaceuticals, Inc | Phase 1 |
Clinical Trial Summary for Poziotinib
Top disease conditions for Poziotinib
Top clinical trial sponsors for Poziotinib
US Patents for Poziotinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Poziotinib | ⤷ Sign Up | Compounds and methods for inhibiting vacuolar ATPase | University of Southern California (Los Angeles, CA) | ⤷ Sign Up |
| Poziotinib | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Poziotinib | ⤷ Sign Up | Crystalline forms of C.sub.21H.sub.22Cl.sub.2N.sub.4O.sub.2 | Biomed Valley Discoveries, Inc. (Kansas City, MO) Vertex Pharmaceuticals Incorporated (Boston, MA) | ⤷ Sign Up |
| Poziotinib | ⤷ Sign Up | In vitro model for a tumor microenvironment | HemoShear, LLC (Charlottesville, VA) | ⤷ Sign Up |
| Poziotinib | ⤷ Sign Up | Salt of EGFR inhibitor, crystalline form and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Poziotinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Poziotinib | Australia | AU2017261372 | 2036-05-05 | ⤷ Sign Up |
| Poziotinib | Canada | CA3023278 | 2036-05-05 | ⤷ Sign Up |
| Poziotinib | China | CN107847398 | 2036-05-05 | ⤷ Sign Up |
| Poziotinib | European Patent Office | EP3452003 | 2036-05-05 | ⤷ Sign Up |
| Poziotinib | European Patent Office | EP3981392 | 2036-05-05 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
